Alumis Inc (ALMS)
$12.64
+0.61
(+5.07%)▲
Live
Performance
- $12.00$12.64$12.64
5.06%
Downside
Day's Volatility :5.06%
Upside
0.0%
- $9.54$13.53$12.64
24.53%
Downside
52 Weeks Volatility :29.49%
Upside
6.58%
Returns
| Period | Alumis Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -7.46% | 0.0% |
6 Months | -9.55% | 0.0% |
1 Year | -9.55% | 0.0% |
3 Years | -9.55% | -23.0% |
Highlights
Market Capitalization | 630.5M |
Book Value | -$8.06 |
Earnings Per Share (EPS) | -3.48 |
Wall Street Target Price | 32.33 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | 0.0% |
Return On Equity TTM | 0.0% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -185.1M |
Diluted Eps TTM | -3.48 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -7.3 |
EPS Estimate Next Year | -6.66 |
EPS Estimate Current Quarter | -4.5 |
EPS Estimate Next Quarter | 0.0 |
Analyst Recommendation
Analyst Forecast
What analysts predicted
Upside of 155.78%
Current $12.64
Target $32.33
Technicals Summary
Sell
Neutral
Buy
Alumis Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Alumis Inc | 1.43% | -9.55% | -9.55% | -9.55% | -9.55% |
 Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
 Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
 Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
 Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Alumis Inc | NA | NA | NA | -7.3 | 0.0 | 0.0 | NA | -8.06 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Alumis Inc | NA | $630.5M | -9.55% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Company Information
Organization | Alumis Inc |
Employees | 128 |
CEO | Mr. Martin Babler Ph.D. |
Industry | Miscellaneous |
Discover More
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$12.64
+5.07%
Invesco Bulletshares 2025 Hi
$12.64
+5.07%
Schwab International Dividend Equity Etf
$12.64
+5.07%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$12.64
+5.07%
Lightpath Technologies Inc
$12.64
+5.07%
Vaneck Vectors Global Alternative Energy Etf
$12.64
+5.07%
First Trust Flexible Municipal High Income Etf
$12.64
+5.07%
Drx Dly Reg Bank Bull 3x
$12.64
+5.07%
Graniteshares 2x Long Pltr Daily Etf
$12.64
+5.07%